If you are not happy with the results below please do another search
AstraZeneca announced that it will voluntarily pull Vaxzevria from the global market amid a sharp decline in demand and following the company’s recent admission that its vaccine is linked with a rare side effect.
Published: May 08, 2024 By Neil Versel BioSpace Xaira Therapeutics launched April 23 with $1 billion behind it to apply artificial intelligence to drug discovery and development. It was the largest […]
The companies hope that the drug – an under-the-skin version of a generic antipsychotic medicine called olanzapine – can be used as a once-monthly treatment for patients with the chronic mental disorder.
Today Klick Health announced the three winning entries for its first round of the $1,000,000 Klick Prize. The agency received about 200 submissions, most of which were submitted by teams, not by an individual. Round one awarded $200,000 to three teams.
CEO and founder, Christa Toole, started the company after having spent over 30 years of experience creating value for clients such as VITAS Healthcare, M&M Mars, Genentech, Novartis, Lilly and Culinary Institute of America. She also was one of the founders of Greater Than One, a media and technology agency with a focus on health care, and for the past 24 years had overseen search, social and analytics for all the agency’s clients.
The key leadership appointments will help fuel organizational growth, expand the company’s future-forward analytics and insights solution pipeline, and add to the company’s expertise in paid media. These appointments underscore Real Chemistry’s commitment to bring the best healthcare, technology and client-relationship experts to serve its clients.
With a total revenue of nearly $2.7 billion, Vertex exceeded analyst estimates in the first quarter, bolstered by strong uptake of its cystic fibrosis products.
ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.
In a joint conference event yesterday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy could be definitively linked to the treatment.
The company’s U.S. sales have been boosted by persistently strong demand for Lenalidomide, a generic version of Bristol-Myers Squibb’s (BMY.N) blockbuster cancer drug Revlimid, which was launched in 2022.
